LGALS1 and graft versus host disease: Galectin-1−/− animals have increased susceptibility to autoimmune diseases, such as experimental autoimmune encephalitis (124), and therapeutic administration of galectin-1 has been effective in models of experimental autoimmune encephalitis, collagen-induced arthritis, and graft versus host disease (124, 146, 147).